Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter ...

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug ...

Pharmacological options for the treatment of dry eye syndrome (DES) include both topical agents (typically the preferred form of pharmacologic treatment) and oral systemic drugs. Drugs used in topical ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third ...

Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD; explore the current treatment landscape of dry eye disease. This is a video synopsis/summary of a Stakeholder Summit involving: Ryan Haumschild, ...

Once relatively rare, dry eye disease (DED) is now considered one of the most common — and annoying — eye conditions. Here’s what you need to know about determining if you have it, identifying the ...

Researchers have successfully used a new robot system to improve treatment for debilitating eye disease. Researchers from King's, with doctors at King's College Hospital NHS Foundation Trust, have ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

More than 360 million people around the world suffer from dry eye disease, which is characterized by chronically red, scratchy or irritated eyes. blackday - stock.adobe.com Dry eye disease is no ...

As we age, our eyesight inevitably changes, and so we must focus on new ways to maintain it. Older people with diabetes need to take special care of their vision ...